Separate Assessment of Intestinal and Hepatic First-pass Effects Using a Rat Model with Double Cannulation of the Portal and Jugular Veins

1) Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B.: Identification of rifampin-inducible P450 3A4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest., 90: 1871-1878 (1992).

2) McDonnel, W. M., Scheiman, J. M. and Traber, P. G.: Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology, 103: 1509-1516 (1992).

3) Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).

4) Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. and Kaminsky, L. S.: Characterization of human small intestinal cytochromes P-450. Drug Metab. Disp., 27: 804-809 (1999).

5) Peters, W. H. M., Nagengast, F. M. and van Tongeren, J. H. M.: Glutathione S-transferase, cytochrome P450, and uridine 5'-diphosphate-glucuronosyltransferase in human small intestine and liver. Gastroenterology, 96: 783-789 (1989).

6) Strassburg, C. P., Manns, M. P. and Tukey, R. H.: Expression of the UDP-glucuronosyltransferase 1A locus in human colon. J. Biol. Chem., 273: 8719-8726 (1998).

7) Watcher, V. J., Salphati, L. and Benet, L. Z.: Active secretion and aenterocytic drug metabolism barriers to drug absorption. Adv. Drug. Deliv. Rev., 46: 89-102 (2001).

8) Benet, L. Z. and Cummins, C. L.: The drug effluxmetabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev., 50: S3-S11 (2001).

9) Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., and Wrighton, S. A.: Molecular and physical mechanisms of first-pass extraction. Drug Metab. Dispos., 27: 161-166 (1999).

10) Fisher, M. B., Paine, M. F., Strelevitz, T. J., and Wrighton, S. A.: The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev., 33: 273-297 (2001).

11) Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).

12) Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y. and Wacher, V. J.: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther., 58: 492-497 (1995).

13) Ito, K., Kusuhara, H. and Sugiyama, Y.: Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res., 16: 225-231 (1999).

14) Norikura, R., Yoshimori, T., Murakami, T., Nakanishi, M. and Mizojiri, K.: Studies on the metabolic fate of a new thromboxane A<SUB>2</SUB> receptor antagonist, S-1452 (I): absorption, distribution, metabolism and excretion after single administration to rats. Xenobio. Metab. Disp., (Japanese), 8: 83-96 (1993).

15) Norikura, R., Yoshimori, T., Murakami, T., Nakanishi, M. and Mizojiri, K.: Studies on the metabolic fate of a new thromboxane A2 receptor antagonist, S-1452 (IV): absorption, distribution, metabolism and excretion in dogs and monkeys. Xenobio. Metab. Disp., (Japanese), 8: 113-125 (1993).

16) Upton, R. A.: Simple and reliable method for serial sampling of blood from rats. J. Pharm. Sci., 64: 112-114 (1975).

17) Okamoto, J., Hirai, E., Kitagawa, T. and Matsubara, T.: Capillary gas chromatographic method for the determination of the thromboxane A<SUB>2</SUB> receptor antagonist S-1452 and its metabolites in human plasma. J. Chromatogr., 583: 45-52 (1992).

18) Bischoff, K. B. and Dedrick, R. L.: Thiopental pharmacokinetics. J. Pharm. Sci., 57: 1346-1351 (1968).

19) Wilikinson, G. R. and Shad, D. G.: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 18: 377-390 (1975).

20) Pang, K. S. and Rowland, M.: Hepatic clearance of drugs. I. Theoretical consideration of a well-stirred model and a parallel tube model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 5: 625-653 (1977).

21) Dintman, J. M. and Siliverman, J. A.: Inhibition of P-glycoprotein by D-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res., 16: 1550-1556 (1999).

22) Hirayama, H. and Pang, K. S.: First-pass metabolism of gentisamide: Influence of intestinal metabolism on hepatic formation of conjugates. Drug Metab. Disp., 18: 580-587 (1990).

23) Kwon, Y. and Inskeep, P. B.: Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs. Pharm. Res., 13: 566-569 (1996).

24) Fujieda, Y., Yamaoka, K., Ito, T. and Nakagawa, T.: Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. Pharm. Res., 13: 1201-1204 (1996).

25) Hirayama, H., Morgado, J., Gasinska, I. and Pang, K. S.: Estimation of intestinal and liver first-pass metabolism in vivo. Drug Metab. Disp., 18: 588-594 (1990).

26) Azuma, R., Hirota, T., Manabe, H., Komuro, M. and Kiwada, H.: First-pass of GTS-21 on canine gut wall and liver determined by portal-systemic concentration difference. Eur. J. Pharm. Sci., 14: 159-164 (2001).

27) Ueda, S., Yamaoka, K., Yui, Y., Shigematsu, A. and Nakagawa, T.: Evaluation of capacity limited first-pass effect through liver by three-points sampling in portal and hepatic veins and systemic artery. Pharm. Res., 19: 852-857 (2002).

28) Mizojiri, K., Norikura, R., Yoshimori, T., Nakanishi, M., Iwatani, K., Terui, A., Kikuchi, J. and Nakagawa, Y.: Identification of metabolites of a new thromboxane A<SUB>2</SUB> receptor antagonist, S-1452, in rats. Xenobio. Metab. Disp., (Japanese), 8: 67-81 (1993).